Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

Exclusion Criteria

• •1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing informed consent form
• •2. A history of renal dysfunction (serum creatinine \> 1.8 mg/dL)
• •3. Presence of active infection
• •4. Untreated second malignancy
• •5. Pregnant or breast feeding females (A urine pregnancy test will be obtained in all women of child-bearing age at initial screening prior to study enrollment and administration of chemotherapy.)